How to Vet a Regenerative Medicine Clinic Before You Pay

01

Why this is worth 20 minutes of your time

The FDA has issued consumer alerts specifically about regenerative medicine products including stem cells and exosomes, noting substantial misleading information online about what these products can treat [1]. Its warning on unapproved products from human cells or tissues describes ongoing reports of adverse events, including patient deaths, and states plainly that for such products the FDA "has not reviewed or verified their quality, safety, purity, or potency" [2].

Those are not theoretical risks from bad clinics in another country. The FDA's warning describes products marketed online and used in the United States.

02

Nine red flags

1. "FDA-approved stem cell injection" for arthritis or back pain. For arthritis and spine pain, that approval generally does not exist. Ask which specific product holds approval, then verify.

2. Exosome injections sold as treatment. The FDA's consumer alert names exosomes explicitly. If a clinic sells exosome injections for joints or pain, that alone warrants skepticism.

3. Promises of regrowth or permanent cure. "Regrow your cartilage," "cure your arthritis," "avoid knee replacement for life." No available therapy reliably does this. Anyone certain of the outcome is selling, not practising.

4. A success rate quoted for you personally. Population statistics can be cited with their limits. A clinic guaranteeing your result is overreaching.

5. No product documentation. You should be able to learn the product name, manufacturer, whether it is autologous or donor-derived, whether cells were expanded in a lab, and what sterility and identity testing was performed.

6. Price pressure and financing. Five-figure packages, "today only" discounts, or third-party medical financing pitched before you have had a proper diagnostic evaluation.

7. A consultation with no diagnosis. If nobody examined your joint properly, reviewed imaging, or asked about your goals before recommending an injection, the recommendation is not individualized.

8. No consent document listing real risks. Infection, immune reaction, and — for improperly regulated cell products — tumour formation are the risks that matter. A consent form that lists only "mild soreness" is incomplete.

9. No named, licensed physician responsible for your care. You should know who is performing the procedure, their licence, their training, and who to call if something goes wrong.

03

Questions to ask, and what a good answer sounds like

A clinic that answers honestly will sometimes say "this is not approved for your indication" or "this is not established." That is a sign of integrity, not weakness.

04

Risks that belong in the conversation

• Infection. Joint and soft-tissue infections after injection are a real, documented harm.
• Immune reaction. More likely with donor or foreign tissue than with your own blood.
• Contamination. Products without proper screening and testing can transmit pathogens.
• Tumour formation. A recognized concern with cell products used outside regulated pathways.
• Cost without benefit. Outcomes are not guaranteed and money is generally not recoverable.

If you experience a serious problem after treatment with a regenerative medicine product, the FDA asks patients to report it through MedWatch [3].

05

Where legitimate care actually sits

Regenerative medicine is not all hype. Platelet-rich plasma, for example, is your own blood, prepared and used the same day, and it has a body of trial evidence in specific conditions including knee osteoarthritis and some tendon problems — evidence that is encouraging but not settled. That is a different category from donor-derived, lab-expanded cell products sold for arthritis, where a systematic review found the field remains largely preclinical [4].

The practical distinction: ask what evidence exists for your specific condition, not for regenerative medicine in general.

06

Bottom line

The safest predictor of a legitimate clinic is documentation. Get the product name, its regulatory status, the preparation method, the risks and the total cost in writing before you pay. Be most cautious of certainty — the honest position in this field is "here is what the evidence supports, and here is where it stops."

If you are exploring regenerative options for joint or tendon pain around Langhorne, PA, Cellara Pain Institute will review your diagnosis first and tell you plainly whether a given option is established, experimental, or simply not supported.

07

FAQ

Are all regenerative medicine clinics risky? No. The field includes legitimate, well-documented care. The distinguishing factor is transparency about what is being injected and what the evidence supports for your condition.

What is the single biggest red flag? A confident promise of a specific outcome — regrowth, a cure, or a guaranteed success rate for you personally.

Is "FDA-approved" ever true for regenerative injections? Rarely for arthritis or pain indications. Ask which product holds approval, then verify it directly.

How much should it cost? Costs vary widely. The concerning pattern is a very high total presented with urgency and financing, before a proper diagnostic evaluation.

Where do I report a problem? The FDA asks patients to report adverse events to MedWatch at https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

08

References

1. FDA Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes — https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
2. FDA Patient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues — https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products
3. FDA MedWatch Adverse Event Reporting Program — https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
4. Stem cell therapy for degenerative disc disease: systematic review — https://pmc.ncbi.nlm.nih.gov/articles/PMC12835428/